Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma

Abstract

BackgroundHypoxia is a hallmark of the solid tumor microenvironment and is associated with poor outcomes in cancer patients. The present study was performed to investigate mechanisms underlying the hypoxia-induced phenotypic changes using human malignant mesothelioma (HMM) cells.MethodsHypoxic conditions were achieved by incubating HMM cells in the air chamber. The effect of hypoxia on phenotype changes in HMM cells was investigated by performing in vitro clonogenicity, drug resistance, migration, and invasion assays. Signaling pathways and molecules involved in the more aggressive behaviors of HMM cells under hypoxia were investigated. A two-tailed unpaired Student’s t-test or one-way ANOVA with Bonferroni post-test correction was used in this study.ResultsHypoxic conditions upregulated hypoxia-inducible factor 1 alpha (HIF-1α) and HIF-2α in parallel with the upregulation of its target, Glut-1, in HMM cells. In vitro clonogenicity of HMM cells was significantly increased in hypoxic conditions, but the proliferation of cells at a high density in hypoxia was lower than that in normoxic conditions. The expression levels of HIF-2α and Oct4 were increased in hypoxic HMM cells. The percentage of cells with high CD44 expression was significantly higher in HMM cells cultured in hypoxia than those cultured in normoxia. Hypoxia significantly enhanced the resistance of HMM cells to cisplatin, which occurred through cytoprotection against cisplatin-induced apoptosis. While cisplatin treatment decreased the ratio of Bcl-2 to Bax in normoxic condition, hypoxia conversely increased the ratio in HMM cells treated with cisplatin. Hypoxia increased the mobility and invasiveness of HMM cells. Epithelial to mesenchymal transition was promoted, which was indicated by the repression of E-cadherin and the concomitant increase of vimentin in HMM cells.ConclusionsThe data illustrated that hypoxic conditions augmented the aggressive phenotypes of HMM cells at the biological and molecular levels. The present study provides valuable background information beginning to understand aggressiveness of HMM in tumor microenvironments, suggesting that a control measure for tumor hypoxia may be an effective therapeutic strategy to reduce the aggressiveness of cancer cells in HMM patients.Electronic supplementary materialThe online version of this article (10.1186/s12885-018-4720-z) contains supplementary material, which is available to authorized users.

Epithelial to Mesenchymal Transition in Human Mesothelial Cells Exposed to Asbestos Fibers: Role of TGF-β as Mediator of Malignant Mesothelioma Development or Metastasis via EMT Event

“…Various studies have explored the role of EMT in MM: Casarsa et al [22] showed the importance of EMT markers in MM prognosis, and others [22,23] evaluated the prognostic value of EMT markers in MM. Kim et al [24] proposed HIF-1α as a mediator of MM transformation via EMT event.…”

Mitochondrial ROS Induce Partial Dedifferentiation of Human Mesothelioma via Upregulation of NANOG

“…Most of the studies showed the expression of pluripotency genes and proteins in mesothelioma cell lines, but not in human mesothelium or mesothelioma. This includes OCT4 protein expression [ 27 ], POU5F1 , NANOG and SOX2 gene expression in cell lines [ 28 , 29 ] or cancer-initiating cells [ 30 ]. Conversely, it has been also shown that POU5F1 , NANOG and SOX2 are not expressed in mesothelioma cell lines [ 31 ].…”

New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment

“…Compact aggregation of tumor cells and reduced blood flow can result in tumor tissue hypoxia. Low oxygen levels at the tumor site subsequently facilitate cancer cell stemness and multidrug transporter expression, thus resulting in CDDP resistance [66,67,68,69,70]. Preclinical studies have indicated that antiangiogenic drugs, such as bevacizumab, can improve the flow of tumor vessels (vascular normalization) and the delivery function of coadministrated chemotherapy drugs [83].…”